441
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Potential clinical application of imatinib mesylate in patients with leukemic large granular lymphocytes

&
Pages 1834-1835 | Received 22 Apr 2011, Accepted 28 Apr 2011, Published online: 24 Jun 2011

References

  • Matsumura I, Mizuki M, Kanakura Y. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies. Cancer Sci 2008;99:479–485.
  • Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004;22:247–306.
  • Fedele R, Martino M, Cuzzola M, et al. Imatibib mesylate in T-cell large granular lymphocyte leukemia associated with chronic graft-versus-host disease. Leuk Lymphoma 2011;52:XXX–XXX.
  • Yang J, Liu X, Nyland S, et al. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood 2010;115:51–60.
  • Lamy T, Bauer FA, Liu JH, Li YX, Loughran TP. Clinicopathological features of aggressive large granular lymphocyte leukaemia resemble Fas ligand transgenic mice. Br J Haematol 2000:108:717–723.
  • Gaine P, Rubin PJ. Primary pulmonary hypertension. Lancet 1998;352:719–725.
  • Tajsic T, Morrell NW. Cellular and molecular mechanisms of pulmonary vascular smooth muscle cell proliferationIn: Yuan JX-J, Garcia JGN, West JB, Hales CA, Rich S, Archer SL, editors. Textbook of pulmonary vascular disease. New York: Springer; 2011. pp 323–334.
  • Rossoff LJ, Genovese J, Coleman M, Dantzker DR. Primary pulmonary hypertension in a patient with CD8/T-cell large granulocyte leukemia: amelioration by cladribine therapy. Chest 1997;112:551–553.
  • Chen XH, Bai F, Sokol L, Zhou JM, Ren A, Painter JS. A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood 2009;113:3226–3234.
  • Svegliati S, Olivieri S, Campelli N, Luchetti M, Poloni A, Trappolini S. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007;110:237–241.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.